Atypical endometrial hyperplasia

This phase 2 trial tests whether adding tirzepatide (a weight-loss injection) to a levonorgestrel intrauterine device (LNG-IUD) can eliminate precancerous or early-stage endometrial cancer in overweight or obese women. About 55 women who want to avoid hysterectomy will receive bo…

This study tests whether a 28- to 54-week program of weight-loss medication (semaglutide), a hormone-releasing IUD, diet, and exercise is safe and feasible before surgery in women with early endometrial cancer and a BMI of 40 or higher. Eighty participants will be randomly assign…

This study tests whether tirzepatide, a drug used for diabetes and weight loss, can slow or stop the growth of early-stage endometrial cancer or its precursor (EIN) in women with obesity. Forty participants will receive either tirzepatide or no additional treatment for 4 weeks be…

This study tests whether adding a weight-loss shot (tirzepatide) to standard hormone therapy can better treat early-stage uterine cancer or pre-cancer in overweight women. About 30 participants will either get the standard progesterone IUD alone or the IUD plus tirzepatide. The g…

This observational study will test a new molecular test called CISENDO, which looks at DNA methylation in cells from a routine cervical smear. The goal is to see if it can accurately detect endometrial cancer or precancerous lesions in women at medium-to-high risk. Researchers wi…

This study will ask 50 people aged 35 and older with abnormal uterine bleeding to collect daily urine samples and track their bleeding at home for several months. Researchers will use a home monitor to measure hormone levels and see if certain patterns are linked to uterine cance…